{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:21:34Z","timestamp":1784287294484,"version":"3.55.0"},"reference-count":64,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p> Precision oncology is the field that places emphasis on the diagnosis and treatment of tumors that harbor specific genomic alterations susceptible to inhibition or modulation. Although most alterations are only present in a minority of patients, a substantial effect on survival can be observed in this subgroup. Mass genome sequencing has led to the identification of a specific driver in the translocations of the tropomyosin receptor kinase family (NTRK) in a subset of rare tumors both in children and in adults, and to the development and investigation of Larotrectinib. This medication was granted approval by the US Food and Drug Administration for NTRK-positive tumors, regardless of histology or age group, as such, larotrectinib was the first in its kind to be approved under the premise that molecular pattern is more important than histology in terms of therapeutic approach. It yielded significant results in disease control with good tolerability across a wide range of diseases including rare pediatric tumors, salivary gland tumors, gliomas, soft-tissue sarcomas, and thyroid carcinomas. In addition, and by taking different approaches in clinical trial design and conducting allocation based on biomarkers, the effects of target therapies can be isolated and quantified. Moreover, and considering developing nations and resource-limited settings, precision oncology could offer a tool to reduce cancer-related disability and hospital costs. In addition, developing nations also present patients with rare tumors that lack a chance of treatment, outside of clinical trials. This, in turn, offers the possibility for international collaboration, and contributes to employment, education, and health service provisions. <\/jats:p><jats:p> The reviews of this paper are available via the supplemental material section. <\/jats:p>","DOI":"10.1177\/1753466620938553","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T10:08:11Z","timestamp":1594289291000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries"],"prefix":"10.1177","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3525-4126","authenticated-orcid":false,"given":"Andr\u00e9s F.","family":"Cardona","sequence":"first","affiliation":[{"name":"Clinical and Translational Oncology Group, Cl\u00ednica del Country, Calle 116 No. 9-72, c. 318, Bogot\u00e1, Colombia"},{"name":"Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogot\u00e1, Colombia"},{"name":"Foundation for Clinical and Applied Cancer Research (FICMAC), Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Arrieta","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, Instituto Nacional de Cancerolog\u00eda (INCaN), M\u00e9xico city, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Ruiz-Pati\u00f1o","sequence":"additional","affiliation":[{"name":"Foundation for Clinical and Applied Cancer Research (FICMAC), Bogot\u00e1, Colombia"},{"name":"Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Sotelo","sequence":"additional","affiliation":[{"name":"Foundation for Clinical and Applied Cancer Research (FICMAC), Bogot\u00e1, Colombia"},{"name":"Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataly","family":"Zamudio-Molano","sequence":"additional","affiliation":[{"name":"Foundation for Clinical and Applied Cancer Research (FICMAC), Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zyanya Lucia","family":"Zatarain-Barr\u00f3n","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, Instituto Nacional de Cancerolog\u00eda (INCaN), M\u00e9xico city, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Ricaurte","sequence":"additional","affiliation":[{"name":"Foundation for Clinical and Applied Cancer Research (FICMAC), Bogot\u00e1, Colombia"},{"name":"Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogot\u00e1, Colombia"},{"name":"Pathology Department, Mayo Clinic, Rochester, Minnesota, Estados Unidos"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Raez","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Program, Memorial Cancer Institute (MCI), Florida International University (FIU), Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Polo Peralta","family":"\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, Instituto Nacional de Cancerolog\u00eda (INCaN), M\u00e9xico city, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feliciano","family":"Barr\u00f3n","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, Instituto Nacional de Cancerolog\u00eda (INCaN), M\u00e9xico city, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Rojas","sequence":"additional","affiliation":[{"name":"Foundation for Clinical and Applied Cancer Research (FICMAC), Bogot\u00e1, Colombia"},{"name":"Oncology Department, Cl\u00ednica Colsanitas, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rolfo","sequence":"additional","affiliation":[{"name":"Thoracic Medical Oncology and Early Clinical Trials Unit, University of Maryland, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Karachaliou","sequence":"additional","affiliation":[{"name":"Global Clinical Development, Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Molina-Vila","sequence":"additional","affiliation":[{"name":"Pangaea Oncology, Laboratory of Molecular Biology, Quir\u00f3n-Dexeus University Institute, Barcelona, Catalunya, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rosell","sequence":"additional","affiliation":[{"name":"Germans Trias i Pujol Research Institute and Hospital (IGTP), Badalona, Catalunya, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"bibr1-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2841"},{"key":"bibr2-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.90"},{"key":"bibr3-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1038\/nature07385"},{"key":"bibr4-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1038\/nature08987"},{"key":"bibr5-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1126\/science.1235122"},{"key":"bibr6-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1038\/nature12912"},{"key":"bibr7-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.11.097"},{"key":"bibr8-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx707"},{"key":"bibr9-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.1660"},{"key":"bibr10-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5846"},{"key":"bibr11-1753466620938553","unstructured":"Globocan. Colombia: cancer fact sheet [Internet], https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/170-colombia-fact-sheets.pdf (2018, accessed 25 May 2019)."},{"key":"bibr12-1753466620938553","unstructured":"Globocan. Latin America and the Caribbean: cancer fact sheet [Internet], http:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/904-latin-america-and-the-caribbean-fact-sheets.pdf (2018, accessed 25 May 2019)."},{"key":"bibr13-1753466620938553","unstructured":"Pennic F. The state of value-based care in 2018: 10 key trends to know [Internet], https:\/\/hitconsultant.net\/2018\/06\/18\/value-based-care-trends\/#.XK7LVOhKjIU (2018, 5 February 2019)."},{"key":"bibr14-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx294"},{"key":"bibr15-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000398"},{"key":"bibr16-1753466620938553","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00169","volume":"2","author":"Freedman AN","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"bibr17-1753466620938553","first-page":"6","author":"Marrone M","year":"2014","journal-title":"PLoS Curr"},{"key":"bibr18-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_208339"},{"key":"bibr19-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0118-3"},{"key":"bibr20-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000911"},{"key":"bibr21-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1111\/his.13666"},{"key":"bibr22-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001062"},{"key":"bibr23-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2015-000023"},{"key":"bibr24-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001203"},{"key":"bibr25-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1038\/319743a0"},{"key":"bibr26-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.05.013"},{"key":"bibr27-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2014.12.006"},{"key":"bibr28-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3352"},{"key":"bibr29-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2018.03.011"},{"key":"bibr30-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2016.11.005"},{"key":"bibr31-1753466620938553","unstructured":"Goldman DP, Gupta C, Vasudeva E, et al. The value of diagnostic testing in personalized medicine [Internet]. Forum Health Econ Policy 16, https:\/\/www.degruyter.com\/view\/j\/fhep.2013.16.issue-2\/fhep-2013-0023\/fhep-2013-0023.xml (2013; accessed 27 May 2019)."},{"key":"bibr32-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1080\/23808993.2018.1421858"},{"key":"bibr33-1753466620938553","doi-asserted-by":"crossref","unstructured":"Calderon-Aparicio A, Orue A. Precision oncology in Latin America: current situation, challenges and perspectives [Internet]. Ecancer 13, https:\/\/ecancer.org\/journal\/13\/full\/920-precision-oncology-in-latin-america-current-situation-challenges-and-perspectives.php (2019; accessed 28 May 2019).","DOI":"10.3332\/ecancer.2019.920"},{"key":"bibr34-1753466620938553","unstructured":"Department of Economic and Social Affairs of the United Nations Secretariat. Country classification [Internet], https:\/\/www.un.org\/en\/development\/desa\/policy\/wesp\/wesp_current\/2014wesp_country_classification.pdf (2014; accessed 25 May 2019)."},{"key":"bibr35-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1086\/381709"},{"key":"bibr36-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1126\/science.1076899"},{"key":"bibr37-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2017.0141"},{"key":"bibr38-1753466620938553","doi-asserted-by":"publisher","DOI":"10.2217\/pme.14.59"},{"key":"bibr39-1753466620938553","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2016.01054"},{"key":"bibr40-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0765"},{"key":"bibr41-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.0446"},{"key":"bibr42-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2018.05.009"},{"key":"bibr43-1753466620938553","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21329"},{"key":"bibr44-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2018.08.009"},{"key":"bibr45-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-062016-050343"},{"key":"bibr46-1753466620938553","unstructured":"Dubuque C, Major P, Suarez S, et al. Oncology basket trials: an emerging paradigm shift in trial design treatment approach? [Internet], https:\/\/trinitylifesciences.com\/wp-content\/uploads\/2019\/05\/Oncology_Basket_Trials_-_Trinity_Partners.pdf (2018; accessed 2 February 2019)."},{"key":"bibr47-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.9751"},{"key":"bibr48-1753466620938553","unstructured":"Polley E. Basket and umbrella trial designs in oncology [Internet], https:\/\/med.stanford.edu\/content\/dam\/sm\/cisd\/symposium-May2017-slides\/EricPolley-May2017-symposium.pdf (2017; accessed 2 February 2019)."},{"key":"bibr49-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2012.08.002"},{"key":"bibr50-1753466620938553","first-page":"412614","volume":"2012","author":"Raeppel SL","year":"2012","journal-title":"Int J Med Chem"},{"key":"bibr51-1753466620938553","doi-asserted-by":"crossref","unstructured":"Burris HA, Shaw AT, Bauer TM, et al. Pharmacokinetics (PK) of LOXO-101 during the first-in-human phase I study in patients with advanced solid tumors: interim update [Internet], p.4529. Experimental and Molecular Therapeutics, American Association for Cancer Research, http:\/\/cancerres.aacrjournals.org\/lookup\/doi\/10.1158\/1538-7445.AM2015-4529 (2015; accessed 27 May 2019).","DOI":"10.1158\/1538-7445.AM2015-4529"},{"key":"bibr52-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0443"},{"key":"bibr53-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(16)31947-5"},{"key":"bibr54-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu331.8"},{"key":"bibr55-1753466620938553","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6547"},{"key":"bibr56-1753466620938553","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2014.34.71"},{"key":"bibr57-1753466620938553","unstructured":"FDA. Accelerated approval (COR-NDAACTION-04)\u2014FDA: Vitrakvi (larotrectinib) [Internet], https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211710s000lbl.pdf (2018; accessed 2 February 2019)."},{"key":"bibr58-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30119-0"},{"key":"bibr59-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31701"},{"key":"bibr60-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714448"},{"key":"bibr61-1753466620938553","doi-asserted-by":"crossref","unstructured":"Tan DSW, Lassen UN, Albert CM, et al. Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach. Ann Oncol 29: ix23-ix27, https:\/\/academic.oup.com\/annonc\/article\/doi\/10.1093\/annonc\/mdy279.397\/5140611 (2018; accessed 27 May 2019).","DOI":"10.1093\/annonc\/mdy430"},{"key":"bibr62-1753466620938553","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA2501"},{"key":"bibr63-1753466620938553","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S177051"},{"key":"bibr64-1753466620938553","doi-asserted-by":"crossref","unstructured":"Hyman D, Kummar S, Farago A, et al. CT127: phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi) [Internet]. Atlanta, https:\/\/www.abstractsonline.com\/pp8\/#!\/6812\/presentation\/9845 (2019, accessed 2 February 2019).","DOI":"10.1158\/1538-7445.SABCS18-CT127"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753466620938553","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1753466620938553","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753466620938553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T17:25:58Z","timestamp":1740936358000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1753466620938553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":64,"alternative-id":["10.1177\/1753466620938553"],"URL":"https:\/\/doi.org\/10.1177\/1753466620938553","relation":{},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"article-number":"1753466620938553"}}